| Lawrence Griffith, MD | |
|
600 N Wolfe St, Baltimore, MD 21287-0005 | |
| (410) 955-3116 | |
| Not Available |
| Full Name | Lawrence Griffith |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366407074 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | D07933 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lawrence Griffith, MD Po Box 64250, Baltimore, MD 21264-4250 Ph: () - | Lawrence Griffith, MD 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (410) 955-3116 |
News Archive
Segasist Technologies, a Canadian software company developing next-generation image contouring platforms for biomedical applications, has launched a crowd funding campaign to bring its software Reconcillio on cloud.
Adults in India are substantially more likely to abstain from smoking at home if they are prohibited from smoking at work, a new study has found.
The House voted Wednesday - by a broad bipartisan majority of 406-19 - to repeal health insurers' exemption from federal antitrust laws, the Associated Press/Atlanta Journal Constitution reports. Despite siding with Democrats, "Republican lawmakers complained … that the legislation passed Wednesday was largely symbolic and would have little real impact since states already regulate health insurers." Democrats have argued that repealing the exemption would make the industry more competitive (Werner 2/24).
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.
Scientists have discovered a compound that could lead to new treatments for heart attacks as well as methods to protect hearts during open heart surgery and other situations in which blood flow to the heart is interrupted.
› Verified 4 days ago
Dr. Leonard Anang Sowah, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-706-4619 Fax: 410-706-2062 | |
Dr. Bhavandeep Singh Bajaj, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3345 Wilkens Avenue, Suite L10, Baltimore, MD 21229 Phone: 410-644-4444 Fax: 410-644-4484 | |
Dr. Yonas Sisay, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 822 Guilford Ave, #100, Baltimore, MD 21202 Phone: 410-385-9672 | |
Dr. Stephen John Witanowski, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 2700 Quarry Lake Dr, Suite 280, Baltimore, MD 21209 Phone: 410-469-5544 Fax: 410-585-2867 | |
Dr. Susrutha Kotwal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Mfl Bldg, West Tower, 6th Floor, Baltimore, MD 21224 Phone: 410-550-5018 | |
Dr. Mitesh G Trambadia, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6701 N Charles St Ste 5218, Baltimore, MD 21204 Phone: 443-849-3786 | |
Ronak K Patel, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2000 |